CalciMedica AI Stock Analysis
Want to see CALC full AI Analyst Report?
CalciMedica (CALC) AI Stock Analysis
CalciMedica
(NASDAQ:CALC)
The score is driven primarily by weak financial performance (no revenue, ongoing losses, and substantial cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Corporate events modestly offset risk through restored Nasdaq compliance, but financing actions (ATM/equity issuances and reverse split) reinforce dilution and funding dependence, while valuation metrics offer limited support due to losses and no dividend.
CalciMedica (CALC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $3.84M
- Dividend Yield
- ―
- Average Volume (3M)
- 81.66K
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 0.13
- Revenue Growth
- ―
- EPS Growth
- 45.29%
- Country
- US
- Employees
- 16
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
CalciMedica Business Overview & Revenue Model
Company Description
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach i...
CalciMedica Financial Statement Overview
Summary
Financial profile is weak for profitability and cash generation: TTM shows no revenue, continued losses (net loss ~$15.1M), and significant cash burn (operating and free cash flow about -$18.2M). Balance sheet leverage is low (no debt) with positive equity (~$4.2M), but equity has been volatile historically, and ongoing losses increase reliance on external funding.
Income Statement
12Very NegativeBalance Sheet
38NegativeCash Flow
14Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | -7,000 | 0 | 0 | 0 | 0 | -519.00K |
| EBITDA | -13.76M | -28.09M | -13.64M | -34.19M | -7.64M | -35.30M |
| Net Income | -15.11M | -29.56M | -13.70M | -34.36M | -7.82M | -35.82M |
Balance Sheet | ||||||
| Total Assets | 14.29M | 13.59M | 19.79M | 12.19M | 3.35M | 69.09M |
| Cash, Cash Equivalents and Short-Term Investments | 13.77M | 13.02M | 18.67M | 11.24M | 1.33M | 63.67M |
| Total Debt | 0 | 9.70M | 0 | 0 | 5.36M | 0 |
| Total Liabilities | 10.07M | 20.23M | 5.38M | 4.03M | 12.58M | 4.07M |
| Stockholders Equity | 4.23M | -6.64M | 14.41M | 8.16M | -9.23M | 65.02M |
Cash Flow | ||||||
| Free Cash Flow | -18.20M | -21.21M | -21.15M | -25.81M | -11.76M | -31.99M |
| Operating Cash Flow | -18.19M | -21.18M | -21.15M | -25.73M | -11.76M | -31.50M |
| Investing Cash Flow | -453.00K | 9.55M | -4.42M | 8.88M | -4,000 | 10.75M |
| Financing Cash Flow | 17.75M | 15.21M | 27.97M | 20.90M | 8.48M | 695.00K |
CalciMedica Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CALC, the sentiment is Negative. The current price of 1.22 is below the 20-day moving average (MA) of 1.34, below the 50-day MA of 1.50, and below the 200-day MA of 2.95, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 14.12 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CALC.
CalciMedica Risk Analysis
CalciMedica disclosed 71 risk factors in its most recent earnings report. CalciMedica reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
3 New RisksCalciMedica Peers Comparison
Overall Rating
CALC43Neutral
LTRN42Neutral
PDSB42Neutral
SKYE40Underperform
SNTI39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 43Neutral | $8.41M | -0.27 | -3029.57% | ― | ― | 45.29% | |
| 42Neutral | $5.45M | -0.24 | -456.35% | ― | ― | 32.93% | |
| 42Neutral | $93.85M | -1.61 | -559.99% | ― | ― | 32.24% | |
| 40Underperform | $4.42M | -0.13 | -503.95% | ― | ― | 26.40% | |
| 39Underperform | $8.31M | -0.07 | 3547.64% | ― | ― | 56.67% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| CALC | Calcimedica, Inc. | 1.22 | -14.58 | -92.28% | |
| PDSB | Pds Biotechnology | 0.89 | 0.14 | 18.12% | |
| SKYE | Skye Bioscience, Inc. | 1.00 | -9.00 | -90.00% | |
| LTRN | Lantern Pharma, Inc. | 0.36 | -2.63 | -87.83% | |
| SNTI | Senti Biosciences, Inc. | 0.10 | -1.71 | -94.64% |
CalciMedica Corporate Events
CalciMedica Announces CFO Resignation and Leadership Transition
NeutralOn October 15, 2026, CalciMedica, Inc. announced that Chief Financial Officer and principal accounting officer Stephen Bardin submitted his resignation, effective immediately after the filing of the company’s Quarterly Report on Form 10-Q for the qua...
CalciMedica Establishes $25 Million ATM Stock Program
PositiveOn September 30, 2026, CalciMedica filed a prospectus supplement with the Securities and Exchange Commission to enable sales of up to $25 million of its common stock under an existing at-the-market offering agreement with H.C. Wainwright & Co. This f...
CalciMedica Regains Nasdaq Compliance, Listing Status Stabilized
PositiveOn March 16, 2026, CalciMedica received a notice from Nasdaq that its common stock had traded below the $1.00 minimum bid price for 30 consecutive business days, putting the company out of compliance with Listing Rule 5550(a)(2). The company was give...
CalciMedica Addresses Nasdaq Equity Compliance Amid Bid-Price Risk
NegativeOn August 31, 2026, CalciMedica reported that Nasdaq staff determined the company now satisfies the alternative minimum stockholders’ equity requirement under Listing Rule 5550(b)(1), based on its June 30, 2026 Form 10-Q showing $5.513 million in equ...
CalciMedica Announces One-for-Five Reverse Stock Split
NeutralOn August 27, 2026, CalciMedica filed an amendment to its certificate of incorporation in Delaware to implement a one-for-five reverse stock split and reduce its authorized common shares from 500,000,000 to 100,000,000, effective at 5:00 p.m. Eastern...
CalciMedica Shareholders Approve Key Equity and Governance Changes
PositiveOn August 19, 2026, CalciMedica held its 2026 annual meeting of stockholders, where investors approved an amendment to the 2023 Equity Incentive Plan, increasing available shares by 7,500,000 and broadening the automatic share reserve calculation to...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 13, 2026
